Updated:
Sporos Bioventures
Sporos Bioventures, LLC is a private biotechnology company focused on transforming the drug development process across oncology through its portfolio approach.
Sporos Bioventures
Sporos Bioventures, LLC is a private biotechnology company focused on transforming the drug development process across oncology through its portfolio approach. It catalyzes the rapid development of breakthrough therapies through a portfolio of companies that target novel disease mechanisms in cancer, fibrosis, inflammation, and immune-related diseases. Its pipeline of assets focuses on oncology and immune-related diseases and is generated through external partnerships and its internal biodiscovery platform. The company is headquartered in Houston with operations in New York and Boston.
General information
Firm type
Venture Capital
Year founded
2020
Location
Region
North America
Country
United States
City
Houston
Corporate office
3139 West Holcombe Blvd, Houston, TX 77025, United States
Principals
Alex Cranberg
Founder, Aspect Energy
Rachel Humphrey
CEO, Normunity
Harold Levy
Co-CIO, Iridian Asset Management
Peter Feinberg
Founding Partner, Boxcar Partners
Sector focus
Frequently asked questions
How is Sporos Bioventures structured — is it a fund or an operating company?
Sporos Bioventures is a private biotechnology company that holds equity interests in multiple biopharma entities. It does not present itself as a traditional venture fund with limited partners; rather, it functions as a holding entity with portfolio companies Tvardi Therapeutics and Sporos BioDiscovery. This structure avoids standard fund-life constraints, allowing it to support long-duration oncology development programs.
What is Sporos Bioventures' investment strategy in oncology?
Sporos focuses on developing targeted cancer treatments by attacking cancer-specific vulnerabilities and co-dependencies found in the tumor microenvironment. Its portfolio approach — holding equity in multiple drug-development entities rather than a single company — is designed to diversify scientific risk across different therapeutic programs. This differentiates it from a typical single-asset biotech startup.
Does Sporos Bioventures invest in anything besides oncology?
No. All disclosed portfolio companies — Tvardi Therapeutics and Sporos BioDiscovery — are exclusively engaged in oncology drug development. The firm's published materials contain no mention of investments in other therapeutic areas or sectors outside life sciences.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: